These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 38530366)
1. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. Ruzanov P; Evdokimova V; Pachva MC; Minkovich A; Zhang Z; Langman S; Gassmann H; Thiel U; Orlic-Milacic M; Zaidi SH; Peltekova V; Heisler LE; Sharma M; Cox ME; McKee TD; Zaidi M; Lapouble E; McPherson JD; Delattre O; Radvanyi L; Burdach SE; Stein LD; Sorensen PH J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38530366 [TBL] [Abstract][Full Text] [Related]
2. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Bilke S; Schwentner R; Yang F; Kauer M; Jug G; Walker RL; Davis S; Zhu YJ; Pineda M; Meltzer PS; Kovar H Genome Res; 2013 Nov; 23(11):1797-809. PubMed ID: 23940108 [TBL] [Abstract][Full Text] [Related]
4. ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion. Saulnier O; Guedri-Idjouadiene K; Aynaud MM; Chakraborty A; Bruyr J; Pineau J; O'Grady T; Mirabeau O; Grossetête S; Galvan B; Claes M; Al Oula Hassoun Z; Sadacca B; Laud K; Zaïdi S; Surdez D; Baulande S; Rambout X; Tirode F; Dutertre M; Delattre O; Dequiedt F Nucleic Acids Res; 2021 May; 49(9):5038-5056. PubMed ID: 34009296 [TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
9. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
10. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation. Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219 [TBL] [Abstract][Full Text] [Related]
11. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012 [TBL] [Abstract][Full Text] [Related]
12. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942 [TBL] [Abstract][Full Text] [Related]
13. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma. Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954 [TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650 [TBL] [Abstract][Full Text] [Related]
17. FOXM1 is an oncogenic mediator in Ewing Sarcoma. Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673 [TBL] [Abstract][Full Text] [Related]
18. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455 [TBL] [Abstract][Full Text] [Related]
19. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells. Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771 [TBL] [Abstract][Full Text] [Related]
20. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]